[Frontiers in Bioscience 1, e55-64, August 1,1996]


H. Cody Meissner, M.D.1, and Donald Y.M. Leung, M.D., Ph.D.2

1 Department of Pediatrics, Floating Hospital for Children at New England Medical Center; Tufts University School of Medicine, Boston, MA 02111;

2 Department of Pediatrics; The National Jewish Center for Immunology and Respiratory Medicine; Denver, CO 80262


1. T. Shimozato, M. Iwata & N. Tamura: Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use. Infect Immun 58, 1384-90 (1990)

2. J.P. Antel, M.E. Medof, J.J. Oger, H.H. Kuo & B.G.W. Arnason: Generation of suppressor cells by aggregated human globulin. Clin Exp Immunol 43, 341-56 (1981)

3. W. Stohl,: Cellular mechanisms in the in vitro inhibition of pokeweed mitogen-induced B-cell differentiation by immunoglobulin for intravenous use. J Immunol 136, 4407-13 (1986)

4. D.Y.M. Leung, J. Burns, J. Newburger & R.S. Geha: Reversal of immunoregulatory abnormalities in Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest 79, 468-72 (1987)

5. R.W. Finberg, J.W. Newburger, M.A. Mikati, A. Heller & J.C. Burns: High dose intravenous gamma globulin treatment enhances natural killer cell activity in Kawasaki disease. J Pediatr 120, 376-80 (1992)

6. S. Takei, Y.K. Arora & S.M. Walker: Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 91, 602-7 (1993)

7. T. Kawasaki,: Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jpn J Allergol 16, 178-222 (1967)

8. H.E. Kato, Ichinose, F. Yoshioka, Takechi T, S. Matsunaga, K. Suzuki & N. Rikitake: Fate of coronary aneurysms in Kawasaki disease: Serial coronary angiography and long-term follow-up study. Am J Cardiol 49, 1758-66 (1982)

9.Centers for Disease Control: Kawasaki Disease. New York. Morbidity and Mortality Weekly Reports. 29:61-3, (1980).

10. J.W. Newburger, M. Takahashi, J.C. Burns, A.S. Beiser, K.J. Chung, C.E. Duffy, M.P. Glode, W.H. Mason, V. Reddy, S.P. Sanders, S.T. Shulman, J.W. Wiggins, R.V. Hicks, D.R. Fulton, A.B. Lewis, D.Y.M. Leung, J.D. Waldman, T. Colton, F.S. Rosen & M.E. Melish. Treatment of Kawasaki Syndrome with intravenous gammaglobulin. N Engl J Med 315, 341-7 (1986)

11. K. Furusho, T. Kamiya, H. Nakano, N. Kiyosawa, K. Shinomiya, T. Hayashidera, T. Tamuira, O. Hirose, Y. Manabe & T. Yokoyama: High dose intravenous gammaglobulin for Kawasaki disease. Lancet ii, 1055-8 (1984)

12. J.W. Newburger, M. Takahashi, A.S. Beiser, J.C. Burns, J. Bastian, K.J. Chung, S.D. Colan, C.E. Duffy, D.R. Fulton, M.P. Glode, W.H. Mason, H.C. Meissner, A.H. Rowley, S.T. Shulman, V. Reddy, R.P. Sundel, J.W. Wiggins, T. Colton, M.E. Melish & F.S. Rosen: A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 324, 1633-9 (1991)

13. K. Durongpisitkul, V.J. Gururag, J.M. Park, & C.F. Martin: Prevention of coronary artery aneurysm in Kawasaki disease: Meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatr 96, 1057-61 (1995)

14. A.M. Rauch: Kawasaki syndrome: Review of new epidemiologic and laboratory developments. Pediatr Infect Dis J 6, 1016-21 (1987)

15. H.Y. Yanagawa, Nakamura, M. Yashiro, Y. Fujita, M. Nagai, T. Kawasaki, S. Aso, Y. Imada & I. Shigematsu: A nationwide incidence survey of Kawasaki disease in 1985-1986 in Japan. J Infect Dis 158, 1296-301 (1988)

16. D.Y.M. Leung,: Immunologic aspects of Kawasaki disease. J Rheumatol 17, 15-8 (1990)

17. D.Y.M. Leung,: Kawasaki disease. Curr Opin Rheumatol 5, 41-50 (1993)

18. D.Y.M. Leung, R.L. Siegel, S. Grady, A. Krensky, R. Meade, E.L. Reinherz & R.S. Geha: Immunoregulatory abnormalities in mucocutaneous lymph node syndrome. Clin Immunol Immunopathol 23, 100-12 (1982)

19. D.Y.M. Leung, E.T. Chu, N. Wood, S. Grady, R. Meade & R.S. Geha: Immunoregulatory T cell abnormalities in mucotaneous lymph node syndrome. J Immunol 130, 2002-4 (1983)

20. M. Terai, Y. Kohno, K. Niwa, T. Toba, N. Sakurai & H. Nakajima: Imbalance among T cell subsets in patients with coronary arterial aneurysms in Kawasaki disease. Am J Cardiol 60, 555-9 (1987)

21. S. Furukawa, T. Matsubara, K. Jujoh, K. Yone, T. Sugawara, K. Sasai, H. Kato & K. Yabuta: Peripheral blood monocyte/macrophage and serum tumor necrosis factor in Kawasaki disease. Clin Exp Immunol 48, 247-51 (1988)

22. C.P.J. Maury, E. Salo & P. Pelkonen: Circulating interleukin-1 in patients with Kawasaki disease. N Engl J Med 319, 1670-1 (1988)

23. C.P.J. Maury, E. Salo & P. Pelkonen: Elevated circulating tumor necrosis factor-alpha in patients with Kawasaki disease. J Lab Clin Med 113, 651-4 (1989)

24. Y. Ueno, N. Takano & H. Kanegane: The acute phase nature of interleukin 6: studied in Kawasaki disease and other febrile illness. Clin Exp Immunol 76, 337-42 (1989)

25. D.Y.M. Leung, R.S. Cotran, E.A. Kurt-Jones, J.C. Burns, J.W. Newburger & J.S. Pober: Endothelial activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet 2, 1298-302 (1989)

26. B.A. Lang, E.D. Silverman, R.M. Laxer & A.S. Lau: Spontaneous tumor necrosis factor production in Kawasaki disease. J Pediatr 115, 939-43 (1989)

27. D.Y.M. Leung, R.S. Geha, J.W. Newburger, J.C. Burns, W. Fiers, L.A. Lapierre & J.S. Pober: Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells suceptible to lysis by antibodies circulating during Kawasaki Syndrome. J Exp Med 164, 1958-72 (1986)

28. D.Y.M. Leung, T. Collins, L. Lapierre, R. Geha & J. Pober: IgM antibodies in the acute phase of Kawasaki Syndrome lyse cultured vascular endothelial cells stimulated by g interferon. J Clin Invest 77, 1428-35 (1986)

29. M. Terai, Y. Kohno, M. Namba, T. Umemiya, K. Niwa, H. Nakajima & A. Mikata: Class II major histocompatibility antigen expression on coronary arterial endothelium in a patient with Kawasaki disease. Hum Pathol 21, 231-4 (1990)

30. M. Toyoda, X. Zhang, A. Petrosian, O.A. Galera, S.J. Wang & S.C. Jordan: Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J Clin Immunol 14, 178-89 (1994)

31. P. Marrack. & J. Kappler: The staphylococcal enterotoxins and their relatives. Science 248, 705-11 (1990)

32. P.M. Schlievert,: Role of superantigens in human disease. J Infect Dis 167, 997-1002 (1993)

33. D.J Fast, P.M. Schlievert & R.D. Nelson: Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immunol 57, 291-6 (1989)

34. Y. Choi, J.A. Lafferty, J.R. Clements, J.K. Todd, E.W. Gelfand, J. Kappler, P. Marrack & B.L. Kotzin: Selective expansion of T cells expressing Vb2 in toxic shock syndrome. J Exp Med 172, 981-4 (1990)

35. J. Abe, J. Forrester, T. Nakahara, J.A. Lafferty, B.L. Kotzin & D.Y.M. Leung: Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B. J Immunol 146, 3747-50 (1991)

36. J. Abe, B.L. Kotzin, C. Meissner, M.E. Melish, T. Masato, D. Fulton, F. Romagne, B. Malissen & D.Y.M. Leung: Characterization of T cell repertoire changes in acute Kawasaki disease. J Exp Med 177, 791-6 (1993)

37. B.A. Pietra, J. De Inocencio, E.H. Giannini & R. Hirsch: TCR Vß family repertoire and T cell activation markers in Kawasaki disease. J Immunol 153, 1881-8 (1994)

38. M. Sakaguchi, H. Kato & A. Nishiyori: Characterization of CD4 T helper cells in patients with Kawasaki disease: Preferential production of tumor necrosis factor alpha by Vb2 or Vb8 CD4 T helper cells. Clin Exp Immunol 99, 276-82 (1995)

39. N. Curtis, R. Zheng, J.R. Lamb & M. Levin: Evidence for a superantigen mediated process in Kawasaki disease. Arch Dis Children 72, 308-11 (1995)

40. D.Y. Leung & J.B. Bussel: Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. J Immunol 155, 5018-21 (1995)

41. D.Y. Leung., H.C. Meissner, D.R. Fulton, D.L. Murray, B.L. Kotzin & P.M. Schlievert: Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 342, 1385-8 (1993)

42. Y. Yamashiro, S. Nagata, S. Oguchi & T. Shimizu: Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. J Infect Dis 39, 264-6 (1996)

43. M. Terai, K. Miwa, T. Williams, W. Kabat, M. Fukuyama, Y. Okajima, H. Igarashi & S.T. Shulman: The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis 172, 558-61 (1995)

44. R.P. Sundel, J.C. Burns, A. Baker, A.S. Beiser & J.W. Newburger: Gamma globulin retreatment in Kawasaki disease. J Pediatr 123, 657-9 (1993)

45. H.C. Meissner, P.M. Schlievert & D.Y.M. Leung: Mechanisms of immunoglobulin action: observations on Kawasaki syndrome and RSV prophylaxis. Immunol Rev 139, 109-23 (1994)

46. J.A. Morris, R.E. Blount & R.E. Savage: Recovery of cytopathic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 92, 544-9 (1956)

47. R.M. Chanock, H.W. Kim & A.J. Vargosko: RSV I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia and minor respiratory diseases in children. JAMA 176, 647-53 (1961)

48. C.A. Heilman: Respiratory syncytial and parainfluenza viruses. J Infect Dis 161, 402-6 (1990)

49. N.E. MacDonald, C.B. Hall & S.C.Suffin: Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 307, 397-400 (1982)

50.J.R. Groothuis, K.M. Gutierrez & B.A. Lauer: Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 82, 199-203 (1988)

51. C.B. Hall, K.R. Powell & N.E. MacDonald: Respiratory syncytial virus infection in children with compromised immune function. N Engl J Med 315, 77-81 (1986)

52. W.P. Glezen, A. Paredes, J.E. Allison, L.H. Taber & A.L. Frank: Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 98, 708-15 (1981)

53. C.B. Hall, A.E. Kopelman, R.G. Douglas, J.M. Geiman & M.P. Meagher: Neonatal respiratory syncytial virus infection. N Engl J Med 300, 393-6 (1979)

54. C.B. Hall: Vaccines for respiratory syncytial virus: from ghosts to genetic genies. Semin Infect Dis 2, 191-6 (1991)

55. J. Chin, R.L. Magoffin, L.A. Shearer, J.H. Schieble & E.H. Lennette: Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89, 449-63 (1969)

56. W.K. Hyun, J.G. Canchola & C.D. Brandt: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89, 422-34 (1969)

57. H.W. Kim, J.G. Canchola, C.D. Brandt, G. Pyles, R.M. Chanock, K. Jensen & R.H. Parrott: Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89, 422-34 (1969)

58. V.G. Hemming, G.A. Prince, J.R. Groothuis & G.R. Siber: Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Micro Rev 8, 22-33 (1995)

59. K.A. Ward, P.R. Lambden, M.M. Ogilvie & P.J. Watt: Antibodies to respiratory syncytial virus polypeptides and their significance in human disease. J Gen Virol 64, 1867-76 (1983)

60. V.G. Hemming. & G.A. Prince: Immunoprophylaxis of infections with respiratory syncytial virus: observations and hypothesis. Rev Infect Dis 12, S470-S5 (1990)

61. G.A. Prince, R.L. Horswood & R.M. Chanock: Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 55, 517-20 (1985)

62. J.R. Groothuis, M.J. Levin, W. Rodriguez, C.B. Hall, C.E. Long, H.W. Kim, B.A. Lauer, & V.G. Hemming: Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics: the RSVIG Study Group. Antimicrob Agents Chemother 35, 1469-73 (1991)

63. H.C. Meissner, D.R. Fulton, J.R. Groothuis, R.L. Geggel, G.R. Marx, V.G. Hemming, T. Hougen & D.R. Snydman: Controlled trial to evaluate protection of high-risk infants against respiratory syncytial virus disease by using standard intravenous immune globulin. Antimicrob Agents Chemother 37, 1655-8 (1993)

64. J.R. Groothuis, E.A.F. Simoes, M.J. Levin, C.B. Hall, C.E. Long, W.J. Rodriguez, J. Arrobio, H.C. Meissner, D.R. Fulton, & R.C. Welliver: Prophylactic administration of respiratory syncytial virus immune globulin to high risk infants and young children. N Engl J Med 329, 1524-30 (1993)

[Table of Contents ] [Previous Section]